Have a personal or library account? Click to login
Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats Cover

Metabolic Effects of Two Different Doses of Venlafaxine Therapy on Rats

Open Access
|Nov 2015

References

  1. 1. Engl TJ, Laimer MS, et al. Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice, 2007;61:1356–1370.10.1111/j.1742-1241.2007.01416.x17627711
  2. 2. Crandall JP, Knowler WC, Kahn SK, et al. The prevention of type 2 diabetes. Nature Reviews Endocrinology, 2008;4:382-393.10.1038/ncpendmet0843257304518493227
  3. 3. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH - The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms, Expert Opinion on Drug Safety, 2006;5:157-168.10.1517/14740338.5.1.15716370964
  4. 4. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability, Prim Care Companion. J Clin Psychiatry, 2001;3:22–27.
  5. 5. Masand PS, Gupta S. Long-Term side Effects of Newer-Generation Antidepressants: SSRIS, Venlafaxine, Nefazodone, Bupropion, and Mirtazapine. Annals of Clinical Psychiatry, 2002;14:175-182.10.3109/10401230209147454
  6. 6. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the Dual Mechanisms of Action of Venlafaxine, Arch Gen Psychiatry, 2000;57:503-509.
  7. 7. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmächer T.
  8. 8. Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or Venlafaxine. Pharmacopsychiatry, 2002;35:220-225.10.1055/s-2002-3639012518269
  9. 9. Hummel J, Westphal S, Weber-Hamann B, Gilles M, et al. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. The Journal of Clinical Psychiatry, 2011;72:885-891.10.4088/JCP.09m05853blu21294998
  10. 10. Khanam R, Najfi H, Akhtar M, Vohora D. Evaluation of venlafaxine on glucose homeostasis and oxidative stress in diabetic mice. Hum Exp Toxicol, 2012;31:1244-50.10.1177/096032711244684022751285
  11. 11. Rosen ED, Sarraf P, Troy AE, et al. PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro, Molecular Cell, 1999;4:611–617.
  12. 12. Wasan KM, Looije NA. Emerging Pharmacological Approaches to the Treatment of Obesity, J Pharm Pharmaceut Sci, 2005;8:259-271.
  13. 13. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice, J Clin Invest, 2000;106:523–531.
DOI: https://doi.org/10.1515/amma-2015-0049 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 196 - 199
Submitted on: Dec 9, 2014
Accepted on: Jun 4, 2015
Published on: Nov 7, 2015
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Imre Annamária, Kolcsár Melinda, Groşan Alexandra, M Imre, Dogaru Maria Titica, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.